{"name":"Pharmacyclics LLC.","slug":"pharmacyclics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Ibrutinib Oral Capsule","genericName":"Ibrutinib Oral Capsule","slug":"ibrutinib-oral-capsule","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"MGd","genericName":"MGd","slug":"mgd","indication":"Chronic lymphocytic leukemia (CLL)","status":"marketed"},{"name":"Next-line ibrutinib","genericName":"Next-line ibrutinib","slug":"next-line-ibrutinib","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo Oral tablet to match Venetoclax","genericName":"Placebo Oral tablet to match Venetoclax","slug":"placebo-oral-tablet-to-match-venetoclax","indication":"Control arm in phase 3 clinical trials of venetoclax","status":"phase_3"}]}],"pipeline":[{"name":"Ibrutinib Oral Capsule","genericName":"Ibrutinib Oral Capsule","slug":"ibrutinib-oral-capsule","phase":"phase_3","mechanism":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Mantle cell lymphoma (MCL)","Marginal zone lymphoma (MZL)","Waldenström macroglobulinemia (WM)"],"catalyst":""},{"name":"MGd","genericName":"MGd","slug":"mgd","phase":"marketed","mechanism":"MGd is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells to reduce proliferation and survival of malignant cells.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)"],"catalyst":""},{"name":"Next-line ibrutinib","genericName":"Next-line ibrutinib","slug":"next-line-ibrutinib","phase":"phase_3","mechanism":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Mantle cell lymphoma (MCL)","Marginal zone lymphoma (MZL)","Waldenström macroglobulinemia (WM)"],"catalyst":""},{"name":"Placebo Oral tablet to match Venetoclax","genericName":"Placebo Oral tablet to match Venetoclax","slug":"placebo-oral-tablet-to-match-venetoclax","phase":"phase_3","mechanism":"This is a placebo tablet formulated to match the appearance and administration of venetoclax in clinical trials.","indications":["Control arm in phase 3 clinical trials of venetoclax"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPdDg3MDhmYTZtVy1rdWdoY1paTG40Y0d1VlQ3RDdOalJkZUlYbWJ3aU1jd2pYbEY1ZnpRd2UyNHY1VHZkWnpVUWU3TzlvOHh3SDVtNzE2NTZEdFBYSEpqNlQ2OHY3SFU2X0JPZ25zaW53LVpsWS11ZEhScEFpNFJEZnhMYjh2WnRBWEJtdGg4OFc2ckxWM2ZJWGRWYndvM3ZHQUJxU3NxaDJMYnZET1hwWU5TR2JLOUg1NExNNnZuNjd2QWJ4ZHhHUXdRMEdxSE9XWWdoVkFIemtfNnFyWXotNTFVdGFaZHJ4ckJnWUdMS05lb3NiOVVyeXgwTXVaTzhIT1RZRVVpWUViV3VMSmJoeWhia2g4dm8?oc=5","date":"2026-02-11","type":"pipeline","source":"VitalLaw.com","summary":"PRESCRIPTION DRUGS—5th Cir.:... - VitalLaw.com","headline":"PRESCRIPTION DRUGS—5th Cir.:...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPcU1NU1NQSTQ5bzViUXRYT1JKd0k3RFVEajZfSF9ZelIwNE56WHg1a25OR3YwTm5CNFYzZ3k3SGwwLVBkVW5jeXlxLWRmWk1CRnU5bDllSUNlZFpQQ3gtMWlub1ZiYm1SWTJzQkNtV1ZNR2hmNDRySG4zdldmLWlMdWktVFpyX3N4VkRYc0c4Sk93VXVXeGc?oc=5","date":"2025-10-21","type":"pipeline","source":"pharmaceutical-journal.com","summary":"BRUKINSA: explore the possibilities in CLL - pharmaceutical-journal.com","headline":"BRUKINSA: explore the possibilities in CLL - pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOZnhROEhGV2NwdnRJdzBvMFhiTHJKNUUzc2dwUXpZZnF1M0ZZaExsZUltQmZMMXA4UEU1UFRRY3ZpQXhVdGx0MzllT0VEd1k5VmtGREx2S3lRSDR2aHE0ZDBkN1ZkNHoyYW16R01ENGJJWW1ERXhiTTRfRi1DcjZFcTlvekJHeXlUNjVqd05QZWQ?oc=5","date":"2025-10-02","type":"patent","source":"Fierce Pharma","summary":"AbbVie, BeOne end BTK blood cancer drug patent fight - Fierce Pharma","headline":"AbbVie, BeOne end BTK blood cancer drug patent fight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE04azQyQ25HV3BELW54cnVrS3Qxd29hanYyZjNJMEFtYUwwNERJS2dlMklwblZGc0xnX3NjUFhKNDBHdW1yY2Y2S0VVUjVlN1pKMV9nY3FVbWt1cno4bGIybE1KOHVXWjB4QXZHR1ZFOXI1TXNKdS01Rmhn?oc=5","date":"2025-09-10","type":"patent","source":"BananaIP Counsels","summary":"Pharmacyclics Divisional Patent Application Upheld by Calcutta High Court - BananaIP Counsels","headline":"Pharmacyclics Divisional Patent Application Upheld by Calcutta High Court","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE41a2FfOV9KcXlkZDNjclM4eml4Y2pYYkZWRlc3UHl2LW53Z1Nfc1J6enU5N0N3dmU4UVJ2WVVWN1VwX1IxV3BBT04tVjVoQ0h2d29kdlhRNGxOcUl1eFdIXzZ2OVFOZEJTRGh2OW0yVUdKV2U0WnpJcUtBZ2loQjA?oc=5","date":"2025-07-03","type":"pipeline","source":"The Medicine Maker","summary":"Raquel Izumi - The Medicine Maker","headline":"Raquel Izumi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNcV9kRks2cXd6Zm1RVm9FXzltUFY3UE82WkgyblRWckRSdm0tX0pXa1czNkFDRGVHSFV4WnhJdDRrV1VjVkRVeVE5cUstUTVxcUliMW9rdU1PQzZEM0FwejhzaEhaT0I2VTZwTEpxN1BRWkthSUhxTTMxY3pDanpYTGhFQ05uZGtoNy0taHNHUWJPWThuRzFxa21wVmpwSU9SWlhmX0RlSQ?oc=5","date":"2025-07-01","type":"pipeline","source":"Bloomberg Law News","summary":"AbbVie Denied Freeze on Tennessee Pharmacy Contract Law (1) - Bloomberg Law News","headline":"AbbVie Denied Freeze on Tennessee Pharmacy Contract Law (1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOdjVGbHk4QnNrRlROYWJqQ3Y2emYwc0k5SGQ2dXd6MDNCUnYxaU15V2dVV05JM0M0YnNFTkd0RzZndkVfNDlvcE9UVHU4eXh0UEtmdVBhckoyTkdoQmhuXzAybHdhNXNidjRPZk9vdlI2c19idlFsRUhzQXU3ekw0OFFOMnJxWmhRZHpiTk9MU3ZOZUhqNFhEeVl2Z2NKY2EtRDNKY0NfNFNPQlRzci15VDNreGRMaC1pdE9OMlF4S19LbDlHMEJsUUZqY0VNcmlhV1VQUmd5OGU3d0VhcTIyNQ?oc=5","date":"2025-04-29","type":"regulatory","source":"Business Wire","summary":"U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire","headline":"U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBOc284aHEzZGJDSmJJYko3aG5WbXRmV0lmTkUtOWU1WlBsZnF5ZVpJVjRxRjI2N0FqTnRobFZISE1GbDh0ZXNZMTlqSFNDSWZJY0Fjd2hNNXR5SUlhZnFQMmFrV1Q3MFVqUVBFYnBUWEhBZ2pMV3ppTUdR?oc=5","date":"2024-11-25","type":"trial","source":"Wiley","summary":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia - Wiley","headline":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNbWV2a3VQUTZna0pBMW5BaUpnN09hTGp3VDlJYU5mclZVQUN4Y050WmxHS01sX3NaYXFmZWxoa1pmbjZJNWFfTF9nSXVvSkhIQnVtQkxEbWNoN0g4dlJSX2hHS0wyZFlWWHdhbGFfQ2hLZDFQLUROSFdjaENYdmRlNFpjc3JqekNubXpWa0Q4SVVzN256VVZUNlZocS1GRENDcjNBeHVB0gGrAUFVX3lxTE1XUFlraUF5Tlp6d01kM1dwZVNTWTB0NlFHR1pkV3V3NkJ0TzhYVjRDTno2UHlGWjBhaERCVTV0Wmx1NXQydG1UdkEzam12TjJQcHdIak1qcjdNU2l2TGFJdmpwQUVZNzVlbV92WnIwRTFCY1FfOXRKQXZlc2phU0NaQUE1U1FJY3YtN0tfd1g3WDhxWFV6ai11bDY2RWFLNVQ2MUtFb3BPcVRmQQ?oc=5","date":"2024-08-15","type":"pipeline","source":"PBS","summary":"Here's a list of drugs affected by Biden's latest Medicare pharmaceutical price cuts - PBS","headline":"Here's a list of drugs affected by Biden's latest Medicare pharmaceutical price cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPN3RnQW9tU29pWExSZWFKcmZSaFNTRHotdE90Z3N1N0M3UFlXOVFYVVNMSkxnMTJIT0RtMWRpQkhxWDR5ZGtIZkxyRDVDbEkzVV9SLXpKLW03alI2RWVDMl9UbXAydVRVbVRyeEpHekp5cm5WSDFPNlcwbmVMUHlrMmUzaFhHa1FjQU5aaDE2VFk5NGNqQVB4VWEwTUZpX3NaSE1OQUdyanVJc2pvNEhxeEhYWnZwQy1OLWtPNg?oc=5","date":"2024-04-25","type":"trial","source":"Mintz","summary":"Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out - Mintz","headline":"Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNWVdycnV6SElTQjJMcEJXUmxrWWxXanZlTDJEdHdLRWpLaUlzWjY5R0dGTEw2NVpnZ1padGxKRVhvQUU2M015eWlpX1pBOVR5TGlPbXUwQm56b0ZZSnhZckRBb2pKNHR2UVU4YjBUX3R3OW1ldW9Fak9PSzZteHdIWkJYb0xNRUdlMlhVdndXTWZUWEZrTUtxQtIBVkFVX3lxTFBtQ0NlcVRfZk90dlROTE91NmpDNWdXSFAzU19aRmc1ZkprSlJuZUJJNFU4N0dJQjNaWnRrS01xXzBJR2Y2MmFGVm8tU3BaZ3NWdnB0RnB3?oc=5","date":"2022-10-07","type":"pipeline","source":"Law360","summary":"Alvogen Continues IP Fight Over Cancer Drug Imbruvica - Law360","headline":"Alvogen Continues IP Fight Over Cancer Drug Imbruvica - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNV1dEQVU5Y3BNVTVFckxlRVJTdUF1MUpTeUk4clhWWmc5Ni1Vbi1FclBYV3YwbVZUUW5NWnNSOURWS0x5QzVmM1poSVQ1YUR6YUI2QnktdEpHdjRXRGd3bUZvUGhPTEFoODFKY2Z4cV9jWmYtUDE2aDFscmE5T0had1dLaktCY01ZdGZ5cFMzX1pKSlFEbFNpbU1tMGp4U3NtWVBCN0VaUi0xTVVQOWxQRElnX3k?oc=5","date":"2021-08-19","type":"patent","source":"Reuters","summary":"AbbVie, J&J units' Imbruvica patents upheld by Delaware court - Reuters","headline":"AbbVie, J&J units' Imbruvica patents upheld by Delaware court","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}